Pilot Study Evaluating Safety & Efficacy of a DCBT: NiCord® & UNM CBU to SCD Patients After Myeloablative Therapy
Pilot Study Evaluating the Safety and Efficacy of a Co-Transplantation of NiCord®, a UCB-derived ex Vivo Expanded Population of Stem and Progenitor Cells and a Second, Unmanipulated CBU in Patients with Sickle Cell Disease (SCD).
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease|
- Safety and Tolerability will be measured by acute NiCord® infusional toxicity. [ Time Frame: 24 hours post-infusion ] [ Designated as safety issue: Yes ]
- Assessment of cumulative incidence of donor-derived neutrophil engraftment. [ Time Frame: By Day 42 ] [ Designated as safety issue: Yes ]
- Proportion of transplant-related mortality. [ Time Frame: at 100 days ] [ Designated as safety issue: Yes ]
- Event-free survival. [ Time Frame: at 100 days ] [ Designated as safety issue: Yes ]
- Overall survival. [ Time Frame: at 180 days. ] [ Designated as safety issue: Yes ]
|Study Start Date:||April 2012|
|Estimated Study Completion Date:||March 2015|
|Estimated Primary Completion Date:||August 2014 (Final data collection date for primary outcome measure)|
NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
Umbilical cord blood (UCB) is an alternative stem cell source for hematopoietic stem cell transplantations (HSCT) and can be used for the treatment of various life-threatening diseases, such as hematological malignancies or genetic blood disorders, in such cases where a matched related stem cell donor is not available. However, the major drawback of using this valuable stem cells source is the limited cell dose in a single cord blood unit (CBU), which was shown to be associated with inadequate hematopoietic reconstitution and high risk of transplant-related mortality. To improve outcomes and extend applicability of UCB transplantation, one potential solution is ex vivo expansion of UCB-derived stem and progenitor cells. NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells. NiCord® is based on a novel technology for the ex vivo cell expansion of cord blood derived hematopoietic progenitor cells. By increasing the number of the short and long-term reconstitution progenitor cells transplanted, NiCord® has the potential to enable the broader application of UCB transplantation, and improve the clinical outcomes of UCB transplantation.
The study is designed as a pilot, single center, single arm study, evaluating the safety and efficacy of the co-transplantation of NiCord® with an unmanipulated CBU to patients with SCD following myeloablative therapy.
The total study duration is approximately 220 days, starting with the signing of an informed consent to the last visit on day 180 post-transplant. A long-term post-study follow-up is planned at 6 months post-study completion (1 year post-transplantation), and a long-term follow-up using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry.
The study hypothesis is that the co-transplantation of NiCord® and an unmanipulated unrelated cord blood graft in patients with SCD following myeloablative preparative therapy consisting of hydroxyurea, busulfan, cyclophosphamide and ATG will be safe and will enable cord blood engraftment.
The main study objectives are assessment of the acute toxicity associated with the infusion of NiCord® within 24 hours post infusion, and assessment of cumulative incidence of donor-derived neutrophil engraftment by day 42 following co-transplantation of NiCord® and unmanipulated cord blood grafts. In addition, the proportion of transplant-related mortality at 100 days, event-free survival at 100 days and overall survival at 180 days will be assessed.
Ten evaluable patients recruited for the study should be 2-21 years of age, at least 10 kg in weight, have symptomatic SCD and should be considered as candidates for allogeneic myeloablative HSCT for the treatment of SCD.
|Contact: David Snyder, PhDfirstname.lastname@example.org|
|United States, New York|
|Steven & Alexandra Cohen Children's Medical Center, New York||Recruiting|
|New York, New York, United States, 11040|
|Contact: Joel Brochstein, MD 718-470-3460 JBrochstein@NSHS.edu|
|Principal Investigator: Joel Brochstein, MD|
|United States, North Carolina|
|Duke University Medical Center||Recruiting|
|Durham, North Carolina, United States, 27705|
|Contact: Dr. Joanne Kurtzberg, MD 919-668-1119 email@example.com|
|Principal Investigator: Dr. Joanne Kurtzberg, MD|
|Principal Investigator:||Joanne Kurtzberg, MD||Duke University Medical Center, NC, USA|
|Study Director:||David Snyder, PhD||Gamida Cell ltd|
|Principal Investigator:||Joel Brochstein, MD||Steven & Alexandra Cohen Children's Medical Center, New York|